NASDAQ
AZR
Last Price
US $4.09
KEY FIGURES
MKT CAP
$10.7M
EPS
TTM$-8.43
EPS Growth (1Y)
-
PEG
TTMN/M
P/E
TTMN/M
P/S
TTM-
YIELD
—
GROWTH (5Y CAGR)
Revenue
-
EBITDA
-
Cash flow
Valuation
Financial
Performance
Cash flow to debt coverage
Azora Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.
Free cash flow growth
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Debt-to-equity ratio
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Debt-to-equity trend
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Net debt to EBITDA
Azora Therapeutics, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Azora Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Current ratio
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Return on assets
Azora Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Azora Therapeutics, Inc.'s return on equity of 1.23K%, is higher than 15.00%, indicating good performance
Earnings quality
Azora Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Azora Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Azora Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Azora Therapeutics, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Revenue growth
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Return on invested capital
ROIC -264.70% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Azora Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Azora Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Azora Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.
Base Cash Flow Valuation (DCF)
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Azora Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
Azora Therapeutics, Inc. has insufficient data to evaluate this check.
EV/EBITDA (FY)
Azora Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Azora Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Azora Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Azora Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
1231%
Return on equity
ROIC: -264.70%
Valuation History
-
Price to Earnings
EV/EBITDA: -0.70X
Cash flow
Profit margin
-
Fair Value
Market $4.09
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.